CoChat

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

Puyang, Xiaoling, Furman, Craig, Zheng, Guo Zhu, Wu, Zhenhua J., Banka, Deepti, Aithal, Kiran, Agoulnik, Sergei, Bolduc, David M., Buonamici, Silvia, Caleb, Benjamin, Das, Subhasree, Eckley, Sean, Fekkes, Peter, Hao, Ming-Hong, Hart, Andrew, Houtman, René, Irwin, Sean, Joshi, Jaya J., Karr, Craig, Kim, Amy, Kumar, Namita, Kumar, Pavan, Kuznetsov, Galina, Lai, Weidong G., Larsen, Nicholas, Mackenzie, Crystal, Martin, Lesley-Ann, Melchers, Diana, Moriarty, Alyssa, Nguyen, Tuong-Vi, Norris, John, O'Shea, Morgan, Pancholi, Sunil, Prajapati, Sudeep, Rajagopalan, Sujatha, Reynolds, Dominic J., Rimkunas, Victoria, Rioux, Nathalie, Ribas, Ricardo, Siu, Amy, Sivakumar, Sasirekha, Subramanian, Vanitha, Thomas, Michael, Vaillancourt, Frédéric H., Wang, John, Wardell, Suzanne, Wick, Michael J., Yao, Shihua, Yu, Lihua, Warmuth, Markus, Smith, Peter G., Zhu, Ping, Korpal, Manav · 2018 · Cancer Discovery
Cited by 117

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant breast cancer metastases continue to be dependent on ERα signaling, there remains a critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). In vitro comparisons of H3B-5942 with standard-of-care (SoC) and experimental agents confirmed increased antagonist activity across a panel of ERαWT and ERαMUT cell lines. In vivo, H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERαY537S breast cancer that was superior to fulvestrant. Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERαWT and ERαMUT cell lines and/or tumor models. In summary, H3B-5942 belongs to a class of orally available ERα covalent antagonists with an improved profile over SoCs. Significance: Nearly 30% of endocrine therapy–resistant breast cancer metastases harbor constitutively activating mutations in ERα. SERCA H3B-5942 engages C530 of both ERαWT and ERαMUT, promotes a unique antagonist conformation, and demonstrates improved in vitro and in vivo activity over SoC agents. Importantly, single-agent efficacy can be further enhanced by combining with CDK4/6 or mTOR inhibitors. Cancer Discov; 8(9); 1176–93. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1047

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1229

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 117

Metadata

Authors
Puyang, X., Furman, C., Zheng, G. Z., Wu, Z. J., Banka, D., Aithal, K., Agoulnik, S., Bolduc, D. M., Buonamici, S., Caleb, B., Das, S., Eckley, S., Fekkes, P., Hao, M.-H., Hart, A., Houtman, R., Irwin, S., Joshi, J. J., Karr, C., Kim, A., Kumar, N., Kumar, P., Kuznetsov, G., Lai, W. G., Larsen, N., Mackenzie, C., Martin, L.-A., Melchers, D., Moriarty, A., Nguyen, T.-V., Norris, J., O'Shea, M., Pancholi, S., Prajapati, S., Rajagopalan, S., Reynolds, D. J., Rimkunas, V., Rioux, N., Ribas, R., Siu, A., Sivakumar, S., Subramanian, V., Thomas, M., Vaillancourt, F. H., Wang, J., Wardell, S., Wick, M. J., Yao, S., Yu, L., Warmuth, M., Smith, P. G., Zhu, P., & Korpal, M.
Venue
Cancer Discovery
Published
2018-09-01
Volume
8
Issue
9
Pages
1176-1193
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2871159547
Cited by
117
References
1
FWCI
5.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1229
The paper
Puyang, X., Furman, C., Zheng, G. Z., Wu, Z. J., Banka, D., Aithal, K., Agoulnik, S., Bolduc, D. M., Buonamici, S., Caleb, B., Das, S., Eckley, S., Fekkes, P., Hao, M.-H., Hart, A., Houtman, R., Irwin, S., Joshi, J. J., Karr, C., . . . Korpal, M. (2018). Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.